Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

18.80CAD
17 Nov 2017
Change (% chg)

$0.52 (+2.84%)
Prev Close
$18.28
Open
$18.30
Day's High
$18.87
Day's Low
$18.28
Volume
1,068,222
Avg. Vol
1,399,100
52-wk High
$25.22
52-wk Low
$11.20

Latest Key Developments (Source: Significant Developments)

Valeant announces pricing of private offering of add-on secured notes
Tuesday, 14 Nov 2017 04:10pm EST 

Nov 14 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant announces pricing of private offering of add-on secured notes.‍Has priced its previously announced offering of $750 million aggregate principal amount of its 5.500 pct senior secured notes due 2025​.‍Notes will be additional notes and form part of same series as Valeant's existing 5.500 pct senior secured notes due 2025​.  Full Article

Valeant announces launch of private offering of add-on secured notes
Monday, 13 Nov 2017 07:35am EST 

Nov 13 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant announces launch of private offering of add-on secured notes.Valeant - launched offering of $750 million aggregate principal amount of 5.500% senior secured notes due 2025​.Valeant - ‍new notes will be additional notes and form part of same series as Valeant's existing 5.500% senior secured notes due 2025​.Valeant - ‍intends to use proceeds from offering to repay a portion of its outstanding series F tranche B term loan facilities due 2022.  Full Article

Valeant Pharmaceuticals amends existing credit agreement
Thursday, 9 Nov 2017 08:13am EST 

Nov 9 (Reuters) - Valeant Pharmaceuticals International Inc ::Valeant-Launched amendment to existing credit agreement seeking to reprice term loans remaining outstanding under series f tranche b term loan facility​.Valeant says prior to closing of repricing transaction, co intends to launch, close offering of $750 million principal amount of senior secured notes‍​.Valeant - proceeds from offering will be used to pay down term loan debt outstanding prior to consummation of repricing transaction - SEC filing.Valeant - ‍offering and repricing transaction are anticipated to close in November 2017​.  Full Article

Valeant announces Q3 revenue of $2.22 billion
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant announces third-quarter 2017 results.Q3 revenue $2.219 billion versus I/B/E/S view $2.15 billion.Sees FY 2017 revenue $8.65 billion to $8.8 billion.Q3 GAAP earnings per share $3.69.Q3 earnings per share view $0.88 -- Thomson Reuters I/B/E/S.Valeant - ‍Updates 2017 full-year revenue and maintains adjusted EBITDA (non-GAAP) guidance range despite asset divestitures​.Valeant - ‍As of Nov. 7, 2017, reduced total debt by approximately $6 billion since end of Q1 of 2016​.Valeant - ‍Expect to complete sale of Obagi medical products business before end of year & will use net proceeds to pay down senior secured term loans​.Valeant - ‍Exceeded $5 billion commitment to pay down debt from divestiture proceeds, free cash flow earlier than previously stated timing of feb 2018​.FY2017 revenue view $8.66 billion -- Thomson Reuters I/B/E/S.Valeant - Qtrly ‍adjusted net income of $367 million​.  Full Article

Valeant agrees to sell Sprout Pharmaceuticals unit to former shareholders of Sprout Pharmaceuticals
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant agrees to sell Sprout Pharmaceuticals subsidiary to former shareholders of Sprout Pharmaceuticals.Valeant - ‍In connection with sale, Valeant will provide a $25 million loan to fund initial operating expenses​.Valeant- ‍In connection with sale completion, co to be released from ongoing obligations of original deal to split future profits with former shareholders​.Valeant - ‍Existing litigation against company brought on behalf of former shareholders of sprout will be dismissed with prejudice​.Valeant- In relation to sale completion, "existing litigation against co brought on behalf of former sprout shareholders will be dismissed with prejudice​".Valeant - ‍Affiliate has entered into an agreement to divest Sprout Pharmaceuticals subsidiary​.Valeant - Agreement to divest is in exchange for a 6% royalty on global sales of Addyi(flibanserin) beginning 18 months from signing of sale agreement​.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Ortho Dermatologics announces FDA filing acceptance for IDP-118, novel plaque psoriasis treatment
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-118, novel plaque psoriasis treatment.Valeant - ‍PDUFA date set for June 18, 2018 for IDP-118​‍​.  Full Article

Ortho Dermatologics reports U.S. FDA filing acceptance for idp-118, novel plaque psoriasis treatment
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc ::Ortho Dermatologics announces U.S. FDA filing acceptance for idp-118, novel plaque psoriasis treatment.‍ortho Dermatologics - PDUFA action date for IDP-118 NDA is June 18, 2018​.  Full Article

Valeant, Pershing Square Capital Management, others amend litigation management agreement​
Wednesday, 1 Nov 2017 12:48pm EDT 

Nov 1 (Reuters) - Valeant Pharmaceuticals International Inc ::Says ‍on Oct 30, co, J. Michael Pearson, Pershing Square Capital Management amended litigation management agreement​ - SEC filing.Says ‍amended litigation management agreement extends termination date of agreement from Nov. 1, to and including Dec. 31​.  Full Article

Teva wins generic Uceris patent trial
Tuesday, 31 Oct 2017 09:52am EDT 

Oct 31 (Reuters) - Teva Pharmaceutical Industries Ltd ::Teva wins generic uceris® patent trial.U.S. Court ruled in Teva's favor in patent litigation involving its ANDA directed to generic version of Valeant's uceris (budesonide ER) tablets​.  Full Article